By David Bautz, PhD NASDAQ:NRBO READ THE FULL NRBO RESEARCH REPORT On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced positive topline results for the single ascending dose (SAD) Part 1 of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 6:3 ratio to
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: